BP11000 PLGA 75:25, Carboxyl-Terminated, IV: 0.18–0.75 dl/g, Mw: 15–106 kDa

PLGA 75:25, Carboxyl-Terminated, IV: 0.18–0.75 dl/g, Mw: 15–106 kDa Description

BP11000 is a carboxyl-terminated PLGA 75:25 copolymer engineered across a broad molecular weight (15–106 kDa) and intrinsic viscosity (0.18–0.75 dl/g) range. This combination provides a versatile platform for designing materials with tailored degradation rates, mechanical properties, and processing characteristics. The carboxyl end group enhances hydrophilicity, accelerates early-stage hydrolysis, and serves as a reactive handle for covalent modification—enabling the conjugation of drugs, peptides, or crosslinkers. Suitable for both research and advanced product development, it supports the creation of sophisticated, resorbable biomedical systems.

PLGA 75:25, Carboxyl-Terminated, IV: 0.18–0.75 dl/g, Mw: 15–106 kDa Applications

1.         Controlled Drug Delivery Systems
   - Used as a matrix in microspheres, implants, or injectable depots for sustained release of therapeutics over weeks to months.
   - Functionalised via carboxyl groups to conjugate targeting ligands or prodrugs for enhanced specificity and efficacy.

2.         Tissue Engineering & Regenerative Scaffolds
   - Fabricated into porous scaffolds for bone, cartilage, or soft tissue repair, with degradation rates matched to tissue ingrowth.
   - Surface-modified via carboxyl groups to improve cell adhesion, proliferation, and differentiation.

3.         Functional Coatings & Biointerfaces
   Applied as a hydrophilic, degradable coating on medical devices (e.g., stents, sensors) to improve biocompatibility and control drug elution.
   - Used as a base layer for further biofunctionalisation through carbodiimide or other coupling chemistries.

4.         Advanced Material Development
   - Serves as a macroinitiator or building block for synthesising block copolymers, hydrogels, or composite materials with customised properties.
   - Employed in research to study structure-property-degradation relationships in biodegradable polymer systems.

PLGA 75:25, Carboxyl-Terminated, IV: 0.18–0.75 dl/g, Mw: 15–106 kDa Packing

The product is sealed in multi-layer, moisture-barrier aluminised pouches under vacuum or inert atmosphere to prevent hydrolysis and oxidation. Each pouch includes desiccant and is housed in a rigid, insulated outer container for physical and thermal protection during transport. Available in sizes from R&D samples (e.g., 5 g, 10 g) to bulk quantities (kg scale). Custom packaging, labelling, and documentation are available upon request. For long-term stability, store at –20°C or below 4°C in a dry environment.

Additional Information

Carboxyl-terminated PLGA 75:25 represents a strategically versatile biomaterial that bridges tunable degradation kinetics with chemical functionality. The broad Mw/IV range allows researchers and engineers to precisely match material behaviour to application timelines—from short-term drug pulses to long-term implant support. The presence of the carboxyl group not only modulates degradation but also opens pathways to advanced biomaterial engineering through conjugation, crosslinking, and surface modification.

Stanford Advanced Materials (SAM) is dedicated to providing high-quality, specialty polymers for advanced applications. Our technical support team is available to assist with material selection, customisation, and integration into your product development process.

Regulatory Note: This material is intended for research and industrial use. It is the customer's responsibility to ensure compliance with all applicable safety, regulatory, and quality standards for their specific application and region.